Life Sciences Archive » March, 2010

Life Sciences - March, 2010

216 articles

• Pfizer Reveals $35M Payout To Docs, Hospitals In '09
• Allstate Owes Wyeth Defense For Ativan Suits: Judge
• Arthrex, DePuy Reach Accord On ACL Patent Suit
• Pfizer Not Excited About Teva's Generic Viagra
• Bayer Fails To Scrap Aspirin Marketing MDL
• Alphapharm Drops Antitrust Claims In Treximet IP Suit
• Fiduciary Duties In Delaware LLC Agreements
• Cephalon Off-Label Class Action Won't Be Reopened
• DNA — Not Patentable Subject Matter ...
• Astra Told To Pay Dr. Reddy's Fees In Prilosec Suit
• Gene Patent Ruling Could Shake Up Biotech
• Bayer Keeps Some Expert Opinions Out Of Trasylol MDL
• Plaintiff-Side Work For BigLaw Can Bring Profit, Pain
• Sandoz Seeks To Appeal Ruling In Effexor Spat
• Does Next Justice Work Across Street From Obama?
• Australian Creditors OK'd To Sue Over Lehman Losses
• J&J Unit Raided In Japanese Competition Probe
• Sidley Life Sciences Patent Pro Joins Quinn Emanuel
• Biosimilars Pathway: A Far Cry From Hatch-Waxman
• MDCO Sues Again For Extension Of Angiomax Patent
• Private Employers Push To Repeal Retiree Drug Tax
• Astellas Wins Look At OSI's Books Amid $3.5B Bid
• Antitrust Claims Survive In Cephalon Pay-To-Delay War
• Sandoz Antitrust Claims Nixed In Bayer's Yaz IP Suits
• Merck Deal, With $3.5M In Fees, OK'd Over Objections
• 7th Circ. Sends Bayer HIV Claims To Taiwan
• Workers Drop Doffing Claim In Bristol-Myers Suit
• Fed. Circ. Refuses To Nix Bayer's Animal Drug IP Suit
• AGA To Pay $35M To End Medtronic Stent Patent Suit
• Fed. Circ. Revives Enzo, Applera DNA Patent Case
• Judge Allows Baxter AWP Qui Tam Suit To Proceed
• KV Pharmaceutical ERISA Class Action Tossed
• Purchasers' Antitrust Suits Over Generic Plavix Tossed
• Plaintiffs' Lawyers Seek MDL For Pain Pump Suits
• Jury Hands $142M Win To Kaiser In Neurontin Battle
• Bayer Eludes Suit Over Multivitamin Marketing
• Frommer Lawrence, Fox Rothschild Add Darby Attys
• Mylan Antitrust Suit Over Mirapex Patent Sent To Del.
• EU Seeks Recall Of Acino Blood Thinner Clopidogrel
• The Written Description Requirement: It's Still Here
• Restitution Can Leave D&O Policyholders High And Dry
• Reverse Payment Suit Over Generic K-Dur Tossed
• Fed. Circ. Upholds Illumina Win In DNA Patent Spat
• Genzyme Says FDA Inspectors Will Oversee Plant
• Stryker Can't Escape Punitive Damages In Pump Suit
• Akin Gump Buys Democratic Lobby Boutique
• Transitions Optical — A Lens On Exclusive Dealing
• AstraZeneca OT Class Action Halted On Appeal
• Biogen Targets GSK's Cancer Drug Arzerra In IP Suit
• Stage-Setting For Circ Split: Generic Drug Preemption?
• Teva's $70M ARS Suit Against Deutsche Tossed
• Qui Tam Relator Barred From Suing Purdue: 4th Circ.
• Fed. Circ. Overturns $1.1M Pressure Products IP Win
• Medtronic Hit With Antitrust Suit Over Spine Treatments
• Axonyx Off Hook For Alzheimer's Drug Securities Suit
• AMRI, Sanofi Ask Judge To Block Generic Allegra
• Physician Payment Reporting Obligations: A Reality
• Walgreen To Cough Up $6M Over Wal-Born Claims
• Ariad Ruling Bolsters Written Description Requirement
• Morgan Lewis Reps Perrigo In $808M PBM Deal
• Alcon Lens Patent Suit Headed To Trial In One Piece
• Sanofi, Toshiba, Others Hit With False Marking Suits
• Ch. 11 Barred Nutrition Bar Maker's Bonuses: Trustee
• Jury Hands Covidien $4.8M In Surgical Device IP Case
• Patent Deemed Invalid In Edwards Heart Valve Suit
• Shire, Nostrum Strike Patent Deal Over Epilepsy Drug
• Obama Signs Health Care Bill As GOP Eyes Repeal
• Medical Experts Allowed In Pfizer Securities Suit
• FDA Suspends Use Of GSK's Rotavirus Vaccine
• Follow-On Biologics: Is Your Patent Portfolio Ready?
• Fed. Circ. Reaffirms Written Description Doctrine
• McWane To Pay Up To $12M For Ala. PCB Cleanup
• FDA Investigates Boston Scientific Defibrillator Recall
• Health Care Bill Heads To Obama's Desk
• Cell Therapeutics Sued Over 'False' New Drug Filings
• Guidant ERISA Plaintiffs Seek OK For $7M Settlement
• Supreme Court Won't Hear Tenn. Fen-Phen Case
• NJ Jury Finds For AstraZeneca In 1st Seroquel Verdict
• Alcon Shareholder Drops Bid To Block Novartis Deal
• Duane Reade Denies Owing Kasowitz Benson $7M Fee
• Norvir And The Difficulties In Analyzing Bundling
• Sanofi, Dabur Patent Dispute Over Eloxatin Survives
• Chantix MDL Plaintiffs Roll Out Master Complaint
• St. Jude Medical In Hot Water Over 'False' Financials
• Ex-Biovail Exec Can't Dodge SEC Fraud Suit
• International Trademark Filings Down 16%: WIPO
• Pristiq-Related ERISA Suit Against Wyeth Gets Booted
• Lilly Takes Aim At Synthon Over Adcirca ANDA
• Pay-For-Delay Ban Dropped From Health Care Bill
• Pfizer Drops Suit Against Lilly Over Viagra Patent
• Former King & Spalding Partner Forms IP Boutique
• Solvay Settles Estratest False Marketing Suit For $16M
• Medtronic ERISA Suit Over $510M IP Payouts Tossed
• Claims Pared In Dey, Sepracor IP Fight Over Brovana
• Kirkland Represents Teva In $5B Ratiopharm Deal
• Focusing On Food Labeling Enforcement
• Firm Pressures Drive More Partners In-House
• 2nd Circ. Seeks Input On Time Bars In Ephedra Case
• Top DOJ Health Fraud Cop Heads To Arnold & Porter
• Purdue To Settle OxyContin Antitrust MDL: Atty
• Tentative Deal Struck In Gilead Securities Action
• Fredrikson & Byron Reps Medtronic In $3B Debt Offering
• MDCO Gets 2nd Shot At Angiomax Patent Extension
• Asahi Kasei Ends Suit Over $91M Arbitration Award
• Mylan, Takeda Bury Hatchet In Diabetes Drug Feud
• Astellas Attempts To Oust OSI Board In Takeover Bid
• Cephalon Goes After Lupin In 6th Nuvigil Patent Suit
• Alpharma To Pay $42.5M Over Morphine Marketing
• Schering, Neutrogena Ads Are Both Misleading: Judge
• Inventor Tafas Seeks Fees In Suit Over USPTO Rules
• FTC Warning Letters: A New Era Of Enforcement?
• Trilipix ANDA Spurs Abbott, Fournier To Sue Impax
• On The Rise: Corporate Carveouts In The US
• Teleflex Issues IV Recall Over Possible Contamination
• KV Pharma Dodges WARN Act Class Action
• Boston Scientific Recalls 2 Types Of Defibrillator
• FDA Discovers Slew Of Quality Issues At Amylin Plant
• Cephalon Patent Suit Over Amrix Survives Dismissal
• FDA Slaps Black Box Warning On Plavix
• Pfizer Asserts 2nd Lyrica Patent Against Mylan
• Kaiser Asks To Admit 'Snake Oil' Barb In Neurontin Trial
• Fresenius Infringes Sanofi's Eloxatin Patent: Judge
• Sanofi To Pay $15M To Settle Sex Bias Class Action
• OSI Board Rejects Astellas $3.5B Bid
• Antitrust Enforcement Of Hospital Consolidations
• Fed. Claims Court Finds No Thimerosal-Autism Link
• Ranbaxy, Takeda Strike Licensing Deal Over Actos
• Shimadzu Resolves Caliper DNA Patent Suit
• CCS Medical's Ch. 11 Plan Approved
• IntelliPharmaCeutics, Elan Settle Focalin Patent Spat
• IP Boutique Darby & Darby To Close Down
• Medivation Sees Shareholder Ire Over Alzheimer's Drug
• Inyx USA Wins Reorganization Plan Approval
• Roxane Agrees To Hold Off On Generic Asacol
• Teen's Suit Against Teva Over Acne Drug Survives
• BMS, Novartis Sue Teva Over HIV Drug Reyataz
• Abbott Ordered To Turn Over E-Mail To Depakote Probe
• Corp. Counsel Warn Firms Not To Slack On Diversity
• Abbott Labs To Buy Facet Biotech For $450M
• Teva Sues Mylan Over Seasonique ANDA
• GlaxoSmithKline Infringes Antibody Patent: Genentech
• Wyeth, Biovail Deal Over Generic Effexor Wins OK
• Feds Probe Medtronic's Link To Mass. Clinic
• Sanofi Loses Injunction Bid In Generic Eloxatin Spat
• Wilson Sonsini Lures Back Cytokinetics GC
• Smith & Nephew Infringed Wound Treatment IP: Jury
• Allen & Overy Reps Novartis In $5B 3-Part Bond Issue
• Biovail Targets Paddock Over Aplenzin ANDA
• Calif. Appeals Court Backs MDA Preemption Clause
• Watson To License Takeda's Actos In Patent Deal
• Clarifying The Standard For Transfer In Eastern Texas
• GSK Tries To Axe Wellbutrin Consumer Antitrust Suit
• Supply Cos.' Antitrust Claims Against Hospitals Tossed
• GSK Tries To Halt Teva's Generic Combivir Launch
• Linklaters, Fried Frank Advise On Sanofi, Merck Deal
• Suggestions For Improving USPTO Re-Examinations
• Actavis Settles Mass. Medicaid Price Claims For $4M
• Watson's Opana ANDA Triggers Endo, Penwest Suit
• FDA Chief Walks Tightrope In 2011 Budget Talks
• National Union Says No To Forba Dental Scam Suit
• $1M Trimmed From $4.8M Award Over Remicade Ads
• Cost-Containment And The Need For Health Courts
• Sanofi-Aventis Units Look To Toss False Claims Suit
• Kinder Morgan, Ethanol Co. End Plant Explosion Feud
• Law360 Product Liability Editorial Advisory Board
• Graceway, 3M TRO Request In Nycomed Case Denied
• OxyContin Buyers Resolve Purdue Antitrust Claims
• Merck's Patent Tactics Violate Antitrust Law: Suit
• Supreme Court Narrows Scope Of Speedy Trial Act
• Celgene, Novartis Resolve ADHD Patent Suits
• 11th Circ. Upholds Dismissal Of Paxil Suicide Case
• Supreme Court To Tackle Vaccine Injury Preemption
• Atty Sanctions Sought In Merck-Schering Merger Suit
• AndroGel Buyer Seeks 2nd Shot At Pay-For-Delay Suit
• AstraZeneca Squashes Anasthetic Warning Suit
• DuPont, Others Pledge $30M To Promote Legal Diversity
• Cooper Cos. Fails To Shake Securities Class Action
• Jury To Decide Secrets Spat Between Doctor, Mayo
• Seattle IP Veteran Tellekson Leaps To Fenwick
• 'Intellact' Trademark Suit Survives Intel Dismissal Bid
• Australian Ruling Opens Door For 100s Of Vioxx Claims
• 9th Circ. Says No To Calif. Medicaid Cuts
• 40 Cases In Aredia, Zometa MDL Survive Dismissal Bid
• Willful Infringement Post-Seagate
• Evolving With Affirmative Defense Pleading Standard
• GAO Issues Scathing Review Of FDA Probe Oversight
• Nestle, Others Targeted By FDA Over Misleading Labels
• Pfizer Patent Adjustment Fight Remanded To USPTO
• 8th Circ. Upholds Another Dismissal In Baycol MDL
• Pfizer Spits Out Class Cert. In Listerine Ad Suit
• KV Unit Ethex To Pay $28M In Oversize Pill Case
• FDCA Precludes Wyeth Protonix Lanham Suit: Court
• Boehringer Seeks To Divide Claims In AWP Case
• AstraZeneca Escapes Liability In Pain Pump Suit
• Prilosec Food Poisoning Suit Gets The Boot
• Skadden Adds Patent Litigators From Dechert
• Boston Scientific Cross-Appeals Stent Patent Ruling
• Amgen ERISA Case Doesn't Hit Proper Targets: Judge
• $13.5M Award In Mead Formula Ad Spat Upheld
• Utah Court Tosses AG's AWP Suit
• DC Circ. Boosts Teva In Row With FDA Over Merck Drugs
• Sanofi Loses Last-Ditch Bid To Upend Eloxatin Deal
• Arnold & Porter Star Opts For Davis Polk, Not Retirement
• AstraZeneca Slaps Sun Pharma Over Nexium IV Generic
• Ortho, Braun Marked Drugs With Expired Patents: Suits
• Stryker Loses Bid To Toss Pain Pump Liability Suit
• Calif. County Sues GSK Over Alleged Avandia Risks
• Enzo Wins Interference Ruling In Siemens Patent Spat
• Nelson Levine Lures Another Cozen O'Connor Atty
• AstraZeneca To Pay Merck $647M For Drug Stake
• Astellas Ups Ante In $3.5B Hostile Bid For OSI
• Wyeth, Apotex Vie For Quick Win In Effexor Patent Suit
• CVS Hits KV With $100M Claim Over Recalled Drugs
• Merck To Buy Biotech Co. Millipore For $7.2B
• The Art Of Writing License Invitation Letters
• Baxter To Pay Up To $330M To Buy ApaTech